dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-15 and is reviewed periodically as new material appears.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Early occupational studies revealed elevated levels of fluorochemicals, including perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA), in the blood of exposed industrial workers, but cited no ill health effects. From 2005 to 2013, three epidemiologists known as the C8 Science Panel conducted health studies as part of a contingency to a class action lawsuit brought by communities in the Ohio River Valley against DuPont. Based on PFOA blood serum concentrations in 69,000 individuals from around DuPont's Washington Works Plant in Parkersburg, West Virginia, this panel reported probable links between elevated PFOA blood concentration and high cholesterol, ulcerative colitis, thyroid disease, testicular cancer, kidney cancer, delayed puberty onset, and pregnancy induced hypertension and preeclampsia. The findings on thyroid disease and ulcerative colitis have since been supported by further studies. The severity of suspected PFAS-associated health effects can vary based on the length of exposure, level of exposure, and health status. Infants may be exposed to PFAS both gestationally and by transfer from mother to child via breastfeeding. Children and infants may be particularly susceptible to PFAS contamination, with potential symptoms of abnormally small birth weight syndrome, preterm birth, one or more neurodevelopmental disorders, and decreased response to childhood vaccines. A study with a population of 2,525 adults from the US National Health and Nutrition Examination Survey (NHANES) reported hearing losses consistent with dose-response trends.
== Chemical Protein Synthesis == Native chemical ligation of unprotected peptide segments is used to prepare the protein's polypeptide chain, which is then folded to form a protein molecule. In native chemical ligation, a peptide C-terminal thioester reacts with a second peptide that has a cysteine residue at its N-terminus, to give a product with a peptide bond at the ligation site. Multiple unprotected peptide segments can be linked in this way to give the full length polypeptide chain, which is folded to give the target protein molecule. Once the chemical synthesis of an L-protein is achieved, the D-protein enantiomer can be prepared using synthetic peptide building blocks made from D-amino acids and Gly. Convergent synthesis is most effective in preparing long polypeptide chains using synthetic peptide-hydrazides, where the hydrazide can be converted to a thioester for use in native chemical ligation. The hydrazide is stable to native chemical ligation reaction conditions, and can be converted in situ to a reactive peptide-thioester for the next native chemical ligation condensation reaction.
== Olfactory perception == The properties of a compound relating to human olfactory perception includes its odour quality, threshold and intensity as a function of its concentration. The odour quality of a (odour-active) compound is assessed using odour descriptors in sensory descriptive analyses. It shows the sensory–chemical relationship in volatile compounds. The odour quality of a compound may change with its concentration. The absolute threshold of a compound is the minimum concentration at which it can be detected. In a mixture of volatile compounds, only the proportion of compounds present at concentrations above their threshold contribute to the odour. This property can be represented by the odour threshold (OT), the minimum concentration at which the odour is perceived by 50% of a human panel without determining its quality, or the recognition threshold, the minimum concentration at which the odour is perceived and can be described by 50% of a human panel. The intensity of perception of a compound is positively correlated with its concentration. It is represented by the unique psychometric or concentration-response function of the compound.
Mummies, though typically thought of as an Egyptian phenomenon, exist in many cultures and have been found on nearly every continent. The word mummy can refer to both intentionally and naturally preserved bodies and is not limited to one geographic area or culture. Damage of mummified remains can be caused by several factors, including poor environmental conditions, physical damage, and improper methods of preservation. Controlling environmental conditions is highly important in preserving the integrity of mummies. Fungi, pests, and microorganisms that cause decay are some of the possible results of inadequate storage and environmental factors. There are a number of ways to mitigate the effects of improper conditions, however. Methods of stabilizing mummies and halting deterioration include inert gas control, where the mummy is placed in a chamber or bag into which fumigants are introduced; wet sterilization, where solutions are applied to the mummy to repel insects and the growth of fungi; controlled drying, which reduces the relative humidity in order to stop growth of microorganisms; and ultraviolet irradiation, which kills microorganisms. Some previous treatments which were thought to help preserve mummified remains but ultimately led to further damage include curing remains by smoking them and applying solutions of copper salts to exposed skin. The Artefact Lab at the University of Pennsylvania Museum of Archaeology and Anthropology (Penn Museum) provides examples and images of mummy preservation.
In June 2025, protests broke out in Los Angeles after a series of federal immigration raids. As demonstrations continued, President Trump issued a memorandum federalizing up to 4,000 California National Guard troops and deploying U.S. Marines to assist with the response. Newsom objected, calling it an unconstitutional overreach of federal authority. On June 9, the State of California, led by Newsom, filed a federal lawsuit, Newsom v. Trump, challenging the legality of the troop deployment. The complaint argued that the order exceeded the president's statutory powers under 10 U.S.C. § 252 and violated the Tenth Amendment and the Posse Comitatus Act. In April 2025, Newsom called the illegal deportation of Kilmar Abrego Garcia to El Salvador "the distraction of the day" set up by the Trump administration. U.S. Senator Chris Van Hollen criticized Newsom's comment, saying, "I think Americans are tired of elected officials or politicians who are all finger to the wind. Anyone who can't stand up for the Constitution and the right of due process doesn't deserve to lead."
Sources: en.wikipedia.org
The aquaporins (AQPs) are water selective. The aquaglyceroporins are permeable to water, but also to other small uncharged molecules such as glycerol. The third subfamily, with little conserved amino acid sequences around the NPA boxes, include 'superaquaporins' (S-aquaporins). The phylogeny of insect MIP family channels has been published.
In October 2025, Kennedy published a book, How to Test Negative for Stupid: And Why Washington Never Will, which held the top spot on The New York Times Best Seller list for three weeks and remained in the top 10 for 13 weeks. The book sold nearly half a million copies by January 2026. On November 6, 2025, Kennedy introduced two bills that would prevent members of Congress from getting paid during a government shutdown. His proposals came as the then current shutdown was on track to become the longest in U.S. history, leading to federal workers missing paychecks. On May 14, 2026, the Senate unanimously passed Kennedy's resolution to withhold pay from senators during government shutdowns. The resolution takes effect after the November 2026 elections. On August 1, 2025, Kennedy and Senator Elizabeth Warren introduced the Build Now Act, which would incentivize local governments to build more homes by requiring the Department of Housing and Urban Development to remove 10 percent of Community Development Block Grant funding from cities that fail to improve their rate of homebuilding above the national median and reallocate that money to cities whose rate of home building exceeds the national median. Kennedy said he got the idea for the legislation from Canadian politician Pierre Poilievre. The Build Now Act became part of the 21st Century ROAD to Housing Act, which became law on July 11.
== Legacy == Following the dissolution of the Selous Scouts in 1980, most of its white soldiers emigrated to South Africa and were integrated into the South African Special Forces and the South African Police's special units. This formed part of an effort by the SADF to recruit white veterans of Rhodesian counter-insurgency units that was designated Operation Winter. Reid-Daly was among the Selous Scouts who moved to South Africa, and was appointed the head of Transkei Defence Force (the military of the nominally independent 'bantustan' of Transkei) in the early 1980s. He recruited other former Selous Scouts to train the force, but was forced to resign in 1987 after Transkei's rulers were overthrown by a military officer who had previously been trained by the Selous Scouts. The former Selous Scouts contributed to the adoption by the South African security forces of the unit's ruthless tactics. For instance, former Selous Scouts comprised most of the initial personnel of the South African Koevoet unit, and it used similar tactics. This unit was responsible for many human rights violations. The South African Police's Vlakplaas paramilitary hit squad that was established in 1979 was also inspired by the Selous Scouts, as was the Civil Cooperation Bureau that was formed in 1986. Following the end of the Apartheid regime in South Africa some former Selous Scouts joined private military companies. Reid-Daly's memoirs Selous Scouts: Top Secret War, which were first published in 1982, have had a strong influence on the historiography of the Rhodesian Bush War.
=== Manganese electrolysis === During the electrowinning of manganese, the addition of selenium dioxide decreases the power necessary to operate the electrolysis cells. China is the largest consumer of selenium dioxide for this purpose. For every tonne of manganese, an average 2 kg selenium oxide is used.
The preparation of THC was reported in JACS in 1965. That procedure called for the intramolecular alkyl lithium attack on a starting carbonyl to form the fused rings, and a tosyl chloride mediated formation of the ether.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.